Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single ...
Canada
Argentina 
Australia 
Austria 
Brazil 
Germany 
Ireland 
Italy 
Malaysia 
Mexico 
New Zealand 
Poland 
South Africa 
United Kingdom 
United States 
